Read More Pharma Industry News FDA approves Cytokinetics’ MYQORZO for obstructive HCM after SEQUOIA-HCM trial success FDA approves Cytokinetics’ aficamten for obstructive HCM. Find out what this means for cardiologists, patients, and rival Camzyos as MYQORZO prepares to launch. byPallavi MadhirajuDecember 21, 2025